Automated Phenotyping With Artificial Intelligence Predicts Future Advanced Neoplasia Risk in Colitis-associated Low-grade Dysplasia.
The ability to precisely determine future risk of advanced neoplasia (AN; high-grade dysplasia and/or colorectal cancer [CRC]) in patients with ulcerative colitis (UC) and low-grade dysplasia (LGD) is
APA
Johnson B, Eddington H, et al. (2026). Automated Phenotyping With Artificial Intelligence Predicts Future Advanced Neoplasia Risk in Colitis-associated Low-grade Dysplasia.. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. https://doi.org/10.1016/j.cgh.2026.01.037
MLA
Johnson B, et al.. "Automated Phenotyping With Artificial Intelligence Predicts Future Advanced Neoplasia Risk in Colitis-associated Low-grade Dysplasia.." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2026.
PMID
41713829
Abstract
The ability to precisely determine future risk of advanced neoplasia (AN; high-grade dysplasia and/or colorectal cancer [CRC]) in patients with ulcerative colitis (UC) and low-grade dysplasia (LGD) is a major unmet need. Given the uncertainty in existing prognostic data, current guidelines advise incorporating expert opinion into management decisions, which can be challenging and imprecise. In addition to supporting clinician decision-making, having quantitative estimates of cancer risk also increases patients' ability to make informed shared decisions on surgery vs continued intensive surveillance following a LGD diagnosis..